Xenotransplantation

Franklin Hoke's article on Thomas Starzl's bold experiment in xenotransplantation (The Scientist, Sept. 28, 1992, page 1) is one of the most thoroughly researched I've found in a scientific journal. And yet it completely omits the fact that the subject of Starzl's experiment, a 35-year-old unidentified male, was HIV positive. Such an omission cannot have been unintentional. How does one specifically delineate the effects of drugs upon the immune system while conveniently ignoring the fact that

Written byDonald Barnes
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Franklin Hoke's article on Thomas Starzl's bold experiment in xenotransplantation (The Scientist, Sept. 28, 1992, page 1) is one of the most thoroughly researched I've found in a scientific journal. And yet it completely omits the fact that the subject of Starzl's experiment, a 35-year-old unidentified male, was HIV positive. Such an omission cannot have been unintentional. How does one specifically delineate the effects of drugs upon the immune system while conveniently ignoring the fact that this particular immune system was compromised even before the experiment began?

Also, I think the article gave short shrift to Ingrid Newkirk's primary thesis, that is, how many more humans could have been helped with the monies spent for this debacle? If I accept published figures, it costs about $400 to provide prenatal care for expectant mothers. The Starzl experiment cost nearly $175,000, of which the patient paid not a dime. Well over 400 ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies